Evaluation of the Management of Urachal Carcinoma: A Single-Center Experience over 13 Years
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early detection and surgical treatment are key for urachal carcinoma, a rare and aggressive cancer. Adjuvant chemotherapy may improve outcomes, but further research is needed for other therapies.
Area Of Science
- Urologic Oncology
- Surgical Pathology
Background
- Urachal carcinoma is a rare malignancy with high aggressiveness and poor prognosis.
- Diagnosis is often delayed, and standardized clinical treatment guidelines are lacking.
Purpose Of The Study
- To summarize the clinical characteristics, treatment approaches, and outcomes of urachal carcinoma.
- To provide a reference for the diagnosis and treatment of this rare cancer.
Main Methods
- Retrospective analysis of clinical data from 21 urachal carcinoma patients treated between January 2010 and August 2022.
- Follow-up data was collected for all included patients.
Main Results
- Average survival time was 67.1 months; average relapse-free survival was 48.8 months.
- Six patients received adjuvant chemotherapy, and five patients died during follow-up.
- Positive surgical margins were associated with a worse prognosis.
Conclusions
- Early physical examination may aid in early urachal carcinoma detection.
- Surgery remains the preferred treatment for localized disease; lymph node dissection is crucial for staging.
- Adjuvant chemotherapy may improve prognosis, while radiotherapy, targeted therapy, and immunotherapy require further investigation.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.